MedTrace Logo

Repletion of Ergothioneine in Patients With Kidney Failure

NCT06487546 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-01

No results posted yet for this study

Summary

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Conditions

  • Esrd

Interventions

DIETARY_SUPPLEMENT

Ergothioneine

Participants will receive ergothioneine capsule daily for 12 weeks.

OTHER

Placebo

Participants will receive placebo capsule daily for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Tammy Sirich, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2029-04-30
Completion
2030-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487546 on ClinicalTrials.gov